WuXi AppTec plans to build a new site in Singapore
Better serving global partners and advancing healthcare innovation
Better serving global partners and advancing healthcare innovation
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Company raises the annual revenue guidance from mid-teens to high teens
Dr Sai Satish, Sr. Consultant Interventional Cardiologist performs India’s first 3 successful G4-Transcatheter Edge to Edge (G4–TEER) mitral valve repairs
The funds raised in the seed round will be used for research and development of Shri Chyawan Ayurved Product
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
Completion of the demerger of Haleon and share consolidation of GSK
Gansons is based in Thane (Maharashtra, India) with global representation in UK, USA, UAE, Central Asia, South Asia and South-East Asia.
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
ABDM Hackathon Round 1 – Kickstarting Unified Health Interface (UHI) is being held from 14th to 17th July 2022 as a hybrid event
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
The company was directed to submit a plan of compliance by July 15, 2022
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Subscribe To Our Newsletter & Stay Updated